These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 8614376

  • 1. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J, Hohenlöchter B, Schulze-Westhoff P, Schiller M, Zimmermann M, Creutzig U, Ritter J, Jurgens H.
    Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
    [Abstract] [Full Text] [Related]

  • 2. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M, Hohenlöchter B, Schulze-Westhoff P, Zimmermann M, Ritter J, Jürgens H, Boos J.
    Klin Padiatr; 1996 Jun; 208(4):151-9. PubMed ID: 8926681
    [Abstract] [Full Text] [Related]

  • 3. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 4. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 5. [Relation between plasma Ara-C and intracellular Ara-CTP levels by intermediate dose and high dose Ara-C administration in the treatment of AML].
    Yoshida T, Kobayashi K, Nakamura S, Ohtake S, Itoh K, Kanno M, Hirai J, Yasushi, Matsuda TT.
    Gan To Kagaku Ryoho; 1988 Apr 01; 15(4 Pt 1):625-30. PubMed ID: 3162669
    [Abstract] [Full Text] [Related]

  • 6. Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes.
    Koehl U, Hollatz G, Rohrbach E, Visschedyk K, Cinatl J, Kornhuber B, Kreuter J, Mutschler E, Schwabe D.
    Cancer Chemother Pharmacol; 2007 Sep 01; 60(4):467-77. PubMed ID: 17171362
    [Abstract] [Full Text] [Related]

  • 7. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Hug V, Keating MJ, Chubb S.
    Cancer Res; 1980 Mar 01; 40(3):588-91. PubMed ID: 6937239
    [Abstract] [Full Text] [Related]

  • 8. [Is the pharmacokinetic profile of cytarabine clinically relevant?].
    Boos J.
    Klin Padiatr; 1992 Mar 01; 204(4):198-203. PubMed ID: 1518256
    [Abstract] [Full Text] [Related]

  • 9. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [Abstract] [Full Text] [Related]

  • 10. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 11. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Plunkett W, Dixon DO.
    Cancer Res; 1985 Nov 15; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [Abstract] [Full Text] [Related]

  • 12. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF, Huang P, Plunkett W, Gandhi V.
    Clin Cancer Res; 1996 Apr 15; 2(4):653-8. PubMed ID: 9816215
    [Abstract] [Full Text] [Related]

  • 13. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W, Nowak B, Keating MJ.
    Cancer Treat Rep; 1987 May 15; 71(5):479-83. PubMed ID: 3567973
    [Abstract] [Full Text] [Related]

  • 14. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V, Xu YZ, Estey E.
    Clin Cancer Res; 1998 Jul 15; 4(7):1719-26. PubMed ID: 9676847
    [Abstract] [Full Text] [Related]

  • 15. A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo.
    Yamauchi T, Ueda T, Nakamura T.
    Cancer Res; 1996 Apr 15; 56(8):1800-4. PubMed ID: 8620496
    [Abstract] [Full Text] [Related]

  • 16. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
    Tanaka M, Yoshida S.
    Jpn J Cancer Res; 1987 Aug 15; 78(8):851-7. PubMed ID: 3115933
    [Abstract] [Full Text] [Related]

  • 17. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.
    Biochem Pharmacol; 2009 Jun 15; 77(12):1780-6. PubMed ID: 19428333
    [Abstract] [Full Text] [Related]

  • 18. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma.
    Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR.
    J Clin Invest; 1985 Feb 15; 75(2):632-42. PubMed ID: 3871794
    [Abstract] [Full Text] [Related]

  • 19. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM, Rustum YM.
    Cancer Res; 1985 Dec 15; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS.
    Clin Cancer Res; 2005 Dec 01; 11(23):8403-12. PubMed ID: 16322302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.